Digital Therapeutic Innovator NightWare Named by The Observer as One of the Twenty Hot Health Start-ups in the Midwest

- NightWare claims the #3 spot on the list of hottest digital health start-ups across the country;
- Calling the NightWare a ‘Game-Changer,’ Observer experts give clinical stage company a major edge as it heads into next week’s annual JP Morgan Healthcare Investment Conference.

MINNEAPOLIS, MINNESOTA // Jan. 4, 2019 – Digital therapeutics innovator NightWare, a privately-held company that treats Nightmare Disorder for those suffering from PTSD today announced its selection by THE OBSERVER as one of the nation’s hottest digital health companies. Released today, The Observer article highlights twenty digital health and medical device companies from across the country that are revolutionizing their respective fields. NightWare was ranked #3 on this list. Published opening day of the 37th Annual J.P. Morgan Healthcare Investment Conference in San Francisco, the list was compiled by a select number of venture capitalists and health industry experts impaneled by the Observer.

The article, which included a quote from The Medical Alley Association’s Vice President of Intelligence Frank Jaskulke, described NightWare as follows:

*NightWare is a digital therapeutic treatment for Nightmare Disorder, which occurs in approximately 70% of cases of PTSD. This clinical stage company stands to improve outcomes for key veteran and civilian PTSD populations while bringing providers into the age of software-defined behavioral health. According to Frank Jaskulke, the vice president of intelligence at the Medical Alley Association, one of the nation’s preeminent trade organizations for health care and health technology companies, “NightWare is a real game changer. The company could very well become the first FDA-cleared digital therapeutic solution that uses a physical intervention to treat a massive set of complex disorders.”*

The complete original list from The Observer can be accessed [here](#).

“It is such an honor – and surprise – to learn that our young company is already making waves on a national level,” said NightWare CEO and Founder Grady Hannah. “Already in early stage trials, NightWare has seen great efficacy in our pilot study and we look forward to publishing the results of our Randomized Clinical Trial. An opportunity to improve the lives of veterans and those suffering from PTSD is humbling and we’re excited about the direction our company is headed.”

**About NightWare**: NightWare is a digital therapeutics company with a wearable platform designed to treat nightmare disorder, a common affliction that affects those suffering from PTSD (Post-Traumatic Stress Disorder.) The clinical stage company, headquartered in Minneapolis, MN
is working with the VA and other veterans’ service organizations to better serve veteran and law enforcement populations across the United States afflicted by nightmare disorder and PTSD. NightWare is expected to be commercially available in 2020.

For more information please visit: www.nightware.com

For Media Inquiries Media contact: Marika Kelly mkelly@tunheim.com (952)851-1600